Journal of Pain Research (Jan 2021)

Outcomes of the Pediatric Development Plan of Tapentadol

  • Eerdekens M,
  • Radic T,
  • Sohns M,
  • Khalil F,
  • Bulawa B,
  • Elling C

Journal volume & issue
Vol. Volume 14
pp. 249 – 261

Abstract

Read online

Mariëlle Eerdekens, Tatjana Radic, Melanie Sohns, Feras Khalil, Beata Bulawa, Christian Elling Grünenthal GmbH, Aachen, GermanyCorrespondence: Mariëlle EerdekensGrünenthal GmbH, Zieglerstraße 6, 52078 Aachen, GermanyTel +49 241 569 1090Email [email protected]: The opioid analgesic tapentadol was the first pain medication to be developed for the treatment of pain in children under a formal process established by the regulatory authorities. This article summarizes the outcomes of the pediatric development program for tapentadol across the entire age range from birth (including neonates) to adolescents < 18 years of age. In addition, the challenges experienced when designing and conducting the pediatric tapentadol clinical trials as well as the interactions with the regulatory authorities are discussed. As a first outcome, the oral solution of tapentadol was authorized in the EU in 2018 as a new treatment option in the hospital setting for moderate to severe acute pain in children from 2 to < 18 years of age.Keywords: pain, pediatric, regulations, tapentadol, review

Keywords